TLR3 and neoplasm: Despite recent failure of TLR agonists in the clinic [80] and recent work suggesting a possible contribution of TLR3 to tumor progression [56], TLR-based therapies combined with different types of DNA-damaging agents are currently in clinical trials for treatment of many cancer types [81,82].